MTRR: A Protein as A Potential Drug Target (G4552)
MTRR: A Protein as A Potential Drug Target
MTRR (MTRR variant 6) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell antigen receptor (TCR) family and is involved in the regulation of cell survival and proliferation.
MTRR has been identified as a potential drug target in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions has been studied extensively, and several studies have suggested that MTRR may be a promising target for new treatments.
One of the key reasons for the interest in MTRR as a drug target is its ability to interact with several different signaling pathways. MTRR has been shown to play a role in the regulation of cell adhesion, DNA replication, and apoptosis (programmed cell death) . It has also been shown to interact with several different signaling pathways, including T cell signaling, master signaling pathway (HIPK3), and NF-kappa-B signaling.
MTRR has also been shown to play a role in the regulation of inflammation. Studies have shown that MTRR is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12. It has also been shown to interact with several different signaling pathways that are involved in inflammation, including NF-kappa-B signaling and the T-cell signaling pathway.
In addition to its role in inflammation and cell survival, MTRR has also been shown to play a role in the regulation of stem cell proliferation. Studies have shown that MTRR is involved in the regulation of stem cell self-renewal and that it may play a role in the development of cancer.
MTRR has also been shown to play a role in the regulation of tissue repair and regeneration. Studies have shown that MTRR is involved in the regulation of the production of stem cells and that it may play a role in the repair of damaged tissue.
Overall, MTRR is a protein that has been identified as a potential drug target in a variety of diseases. Its ability to interact with several different signaling pathways and its involvement in several different processes in the body make it an attractive target for research and development of new treatments. As further studies continue to be conducted on MTRR, it is likely that new insights will emerge into its role in these and other conditions.
Protein Name: 5-methyltetrahydrofolate-homocysteine Methyltransferase Reductase
Functions: Key enzyme in methionine and folate homeostasis responsible for the reactivation of methionine synthase (MTR/MS) activity by catalyzing the reductive methylation of MTR-bound cob(II)alamin (PubMed:17892308). Cobalamin (vitamin B12) forms a complex with MTR to serve as an intermediary in methyl transfer reactions that cycles between MTR-bound methylcob(III)alamin and MTR bound-cob(I)alamin forms, and occasional oxidative escape of the cob(I)alamin intermediate during the catalytic cycle leads to the inactive cob(II)alamin species (Probable). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMADHC, MTRR and MTR which may contribute to shuttle safely and efficiently cobalamin towards MTR in order to produce methionine (PubMed:27771510). Also necessary for the utilization of methyl groups from the folate cycle, thereby affecting transgenerational epigenetic inheritance (By similarity). Also acts as a molecular chaperone for methionine synthase by stabilizing apoMTR and incorporating methylcob(III)alamin into apoMTR to form the holoenzyme (PubMed:16769880). Also serves as an aquacob(III)alamin reductase by reducing aquacob(III)alamin to cob(II)alamin; this reduction leads to stimulation of the conversion of apoMTR and aquacob(III)alamin to MTR holoenzyme (PubMed:16769880)
The "MTRR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRR comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MTSS1 | MTSS2 | MTTP | MTURN | MTUS1 | MTUS1-DT | MTUS2 | MTUS2-AS1 | MTVR2 | MTX1 | MTX2 | MTX3 | mu-Calpain (calpain 1) | MUC1 | MUC12 | MUC13 | MUC15 | MUC16 | MUC17 | MUC19 | MUC2 | MUC20 | MUC20P1 | MUC21 | MUC22 | MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3
